Pfizer says it is expanding testing of its COVID-19 vaccine in children younger than 12.
After a first-step study in a small number of young children to test different doses, Pfizer is ready to enroll about 4,500 young volunteers at more than 90 sites in the U.S., Finland, Poland and Spain.
The vaccine made by Pfizer and its German partner BioNTech already is authorised for emergency use in anyone 12 and older in the U.S. and European Union.
Enrollment of 5- to 11-year-olds began this week. Those youngsters will receive two vaccine doses of 10 micrograms each - a third of the teen and adult dose - or dummy shots. Enrollment of children as young as 6 months will start in a few weeks using an even lower dose, 3 micrograms per shot.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU